The US FDA has approved once-weekly use of Adlarity, a transdermal patch of donepezil, in 5 mg/day or 10 mg/day formulations to treat patients with mild, moderate or severe dementia associated with Alzheimer’s Disease (AD). The patch, which can be placed by a patient or caregiver on a patient’s back, thigh or buttocks, delivers a consistent dose of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Patients may be switched from 5 mg/day or 10 mg/day oral donepezil directly to Adlarity by their prescriber. Adlarity is a brand of Corium Inc, a US-based biopharmaceutical company.